2023
Developing synthetic tools to decipher the tumor–immune interactome
Weizman O, Luyten S, Lu P, Song E, Qin K, Mostaghimi D, Ring A, Iwasaki A. Developing synthetic tools to decipher the tumor–immune interactome. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2306632120. PMID: 37871202, PMCID: PMC10622925, DOI: 10.1073/pnas.2306632120.Peer-Reviewed Original ResearchConceptsImmune cellsImmune-based therapiesTumor-immune cell interactionsDifferent immunotherapiesRetroviral reportersSensitive tumorsImmune surveillanceTumor subtypesTumor microenvironmentSynthetic Notch receptorCell interactionsCell contactTissue functionTissue locationNotch receptorsVivoOptimal tissue functionCellsComprehensive landscapeImmunotherapyTherapyTumorsImmunogenicitySubtypes
2022
Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
Chow RD, Michaels T, Bellone S, Hartwich T, Bonazzoli E, Iwasaki A, Song E, Santin AD. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. Cancer Discovery 2022, 13: 312-331. PMID: 36301137, PMCID: PMC9905265, DOI: 10.1158/2159-8290.cd-22-0686.Peer-Reviewed Original ResearchConceptsAnti-PD-1 immunotherapyImmune checkpoint blockadeMMRd tumorsNK cellsEndometrial carcinomaICB responseMutation burdenT-cell-driven immunityPhase II clinical trialMMRd endometrial cancersPD-1 inhibitorsMismatch repair-deficient cancersTumor-extrinsic factorsHigh response rateEffector CD8Antitumor immunityEndometrial cancerCancer immunotherapyImmune cellsLonger survivalClinical trialsPrimary resistanceT cellsResponse rateMMRd
2020
Conventional type 2 dendritic cells and natural killer cells mediate control of early metastatic seeding
Weizman O, Krykbaeva I, Bosenburg M, Iwasaki A. Conventional type 2 dendritic cells and natural killer cells mediate control of early metastatic seeding. The Journal Of Immunology 2020, 204: 88.17-88.17. DOI: 10.4049/jimmunol.204.supp.88.17.Peer-Reviewed Original ResearchConventional type 2 dendritic cellsType 2 dendritic cellsImmune cellsMetastatic burdenNK cellsDendritic cellsIntracardiac injectionHost anti-tumor immunityType I IFN-independent mannerAdaptive immune cellsAnti-tumor immunityLocal immune cellsNatural killer cellsSyngeneic mouse modelIFN-independent mannerEarly metastatic seedingMetastatic controlTranscription factor IRF3Killer cellsPrimary tumorMetastatic spreadInnate sensorsMouse modelMetastatic growthMetastatic seeding
2019
Successful application of prime and pull strategy for a therapeutic HSV vaccine
Bernstein DI, Cardin RD, Bravo FJ, Awasthi S, Lu P, Pullum DA, Dixon DA, Iwasaki A, Friedman HM. Successful application of prime and pull strategy for a therapeutic HSV vaccine. Npj Vaccines 2019, 4: 33. PMID: 31396405, PMCID: PMC6671986, DOI: 10.1038/s41541-019-0129-1.Peer-Reviewed Original ResearchHerpes simplex virus type 2PBS control groupRecurrent sheddingControl groupVaginal HSV-2 infectionSimplex virus type 2Herpes simplex virus vaccineRecurrent HSV diseaseTherapeutic HSV vaccinesHSV-2 infectionCombinations of vaccinesGuinea pig modelVirus type 2Imiquimod groupHSV diseaseHSV vaccineRecurrent diseaseRecurrent lesionsRecurrent HSVVaccinated groupGlycoprotein vaccineTrivalent vaccineImmune cellsVirus vaccineGenital tract
2018
Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development
Yockey LJ, Iwasaki A. Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. Immunity 2018, 49: 397-412. PMID: 30231982, PMCID: PMC6152841, DOI: 10.1016/j.immuni.2018.07.017.Peer-Reviewed Original ResearchConceptsFetal developmentHealthy pregnancyImmune responseFetal immune responseRole of interferonPregnancy complicationsProinflammatory cytokinesSuccessful pregnancyCertain infectionsPregnant mothersImmune cellsInflammatory conditionsSevere diseasePregnancyFetal diseaseImmune systemCytokinesCongenital disorderPossible targetsInterferonFetusesInfectionDiseaseMothersComplications
2010
Antiviral immune responses in the genital tract: clues for vaccines
Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nature Reviews Immunology 2010, 10: 699-711. PMID: 20829886, PMCID: PMC3678359, DOI: 10.1038/nri2836.Peer-Reviewed Original ResearchConceptsGenital mucosaT cellsGenital tractHerpes simplex virus type 2Simplex virus type 2Innate immune cellsT cell populationsAntiviral immune responseFemale genital tractPattern recognition receptorsVirus type 2Immune correlatesMemory CD4Memory CD8Viral clearanceHuman papillomavirusImmune cellsMemory lymphocytesSuccessful vaccineHIV-1Immune responseSevere diseaseVaginal epitheliumAdaptive immunityTarget cell type